RSS Mersana Therapeutics: FDA Grants Additional Fast Track Designation To XMT-1660

Currently reading:
 RSS Mersana Therapeutics: FDA Grants Additional Fast Track Designation To XMT-1660

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
10,945
Likes
1,923
Credits
33,627©
Cash
0$
Mersana Therapeutics (MRSN) recently revealed that the FDA has granted an additional Fast Track designation to XMT-1660. This new designation pertains to the treatment of advanced or metastatic breast cancer in patients with either low human epidermal growth factor receptor 2 (HER2) levels or HER2-negative disease. Furthermore, the World Health Organization has approved the international nonproprietary name for XMT-1660, which is emiltatug ledadotin.

In a separate announcement, Mersana Therapeutics disclosed encouraging initial clinical results from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. This compound is Mersana's leading Dolasynthen antibody-drug conjugate (ADC) candidate targeting B7-H4.

"We are enthused by the initial safety, tolerability, and efficacy data for Emi-Le, which demonstrate an exciting and distinctive profile within the B7-H4 field and the broader ADC landscape," stated Martin Huber, CEO of Mersana Therapeutics.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom